News und Analysen
Here's Why bluebird bio's Shares Soared 24% in November
After bluebird bio (NASDAQ: BLUE) updated investors on the presentations it will be making at a key industry conference soon, its shares jumped 24.2% in November, according to S&P Global....
Why 2017 Was a Year to Forget for Merck & Co. Inc.
Better luck next year. That's what Merck & Co. (NYSE: MRK) is hoping for after a disappointing 2017. Merck stock is down year to date by 7%, while the S&P 500 index is up close to 18%.Will....
Why 2017 Was a Year to Forget for Merck & Co. Inc.
Better luck next year. That's what Merck & Co. (NYSE: MRK) is hoping for after a disappointing 2017. Merck stock is down year to date by 7%, while the S&P 500 index is up close to 18%.Will....
2 Top Consumer Staples Stocks to Consider Buying Now -- and 1 to Avoid
Recessions are common enough that you can count on several of them impacting your portfolio over the course of even a 10-year time horizon. That's just one reason why consumer staples stocks --....
2 Top Consumer Staples Stocks to Consider Buying Now -- and 1 to Avoid
Recessions are common enough that you can count on several of them impacting your portfolio over the course of even a 10-year time horizon. That's just one reason why consumer staples stocks --....
Why Immunomedics, Inc. Is Soaring Today
After Immunomedics (NASDAQ: IMMU) shared some positive clinical data with investors, shares of the clinical-stage biotech focused on cancer rose 17% as of 3:10 p.m. EST on Wednesday.Immunomedics....
Why Madrigal Pharmaceuticals Stock Is On Fire Today
Shares of Madrigal Pharmaceuticals (NASDAQ: MDGL) are rocketing higher today after the company announced positive mid-stage results for its experimental non-alcoholic steatohepatitis (NASH)....
BASTIDE : Descriptif du programme de rachat d'actions (AG 30.11.2017)
BASTIDE
Société anonyme au capital de 3.303.261 euros
Siège social :
12, avenue de la Dame, Zone euro 2000
30132 Caissargues
305 635 039 RCS NIMES
Descriptif du programme de rachat d'actions....
BASTIDE : Compte rendu de l'assemblée générale du 30 novembre 2017
BASTIDE LE CONFORT MEDICAL
Société Anonyme au capital de 3.303.261 euros
Siège social : 12, avenue de la Dame, Zone Euro 2000
30132 Caissargues
RCS de NIMES N° B 305 635 039
Compte rendu de....
The Motley Fool Interviews Trupanion Founder and CEO Darryl Rawlings
Trupanion (NASDAQ: TRUP) is one of the largest medical insurance providers for cats and dogs with over 400,000 pets enrolled. However, that represents only a small portion of the over 150 million....
This Double Whammy Caused Regeneron Pharmaceuticals Inc. to Fall 10% in November
Shares of Regeneron Pharmaceuticals (NASDAQ: REGN), a large-cap biopharmaceutical company that develops treatments for eye disorders and other serious medical conditions, tumbled 10% during the....
This Double Whammy Caused Regeneron Pharmaceuticals Inc. to Fall 10% in November
Shares of Regeneron Pharmaceuticals (NASDAQ: REGN), a large-cap biopharmaceutical company that develops treatments for eye disorders and other serious medical conditions, tumbled 10% during the....
This Double Whammy Caused Regeneron Pharmaceuticals Inc. to Fall 10% in November
Shares of Regeneron Pharmaceuticals (NASDAQ: REGN), a large-cap biopharmaceutical company that develops treatments for eye disorders and other serious medical conditions, tumbled 10% during the....
ALPHA MOS : Informations relatives au nombre total de droits de vote
INFORMATIONS RELATIVES AU NOMBRE TOTAL DE DROITS DE VOTE ET D'ACTIONS PREVUES PAR L'ARTICLE L. 233-8 II DU CODE DE COMMERCE ET L'ARTICLE 223-16 DU REGLEMENT GENERAL DE L'AUTORITE DES MARCHES....
Why DaVita Inc. Jumped Higher Today
DaVita (NYSE: DVA) is up 12.8% at 12:35 p.m. EST after announcing that it's selling its medical group to UnitedHealth Group's (NYSE: UNH) health services business Optum for $4.9 billion.....
Why Alnylam Pharmaceuticals Rose 12.7% in November
In response to the company sharing a slew of positive developments with investors, shares of Alnylam Pharmaceuticals (NASDAQ: ALNY), a clinical-stage biotech focused on RNAi therapies, jumped 13%....
Depomed Executes an Exit Strategy for Its Opioid Drug
After reporting that Collegium Pharmaceutical (NASDAQ: COLL) will take over commercializing its top-selling drug, Nucynta, Depomed Inc. (NASDAQ: DEPO) shares rallied 10% yesterday. The pact is....
Here's Why Editas Medicine Inc. Stock Is Slipping Today
Shares of Editas Medicine Inc. (NASDAQ: EDIT), a biotech that aims to correct disease‑causing genes with CRISPR technology, are in retreat following the pricing of a secondary share offering this....
The 2 Likely Reasons Novavax Inc. Rocketed Higher by 25% in November
Shares of Novavax (NASDAQ: NVAX), a clinical-stage small-cap biotech company focused on the development of recombinant nanoparticle vaccines, surged by 25% during the month of November, according....
2 Reasons Geron Corporation Took a Pounding in November
Shares of Geron Corporation (NASDAQ: GERN), a clinical-stage biotech company focused on the development of oncology drugs, sank 12% during the month of November, according to data from S&P....
5 Key Things to Know About This Leading Marijuana Stock's Future
You can count the number of pure-play marijuana stocks with a market cap of around $3 billion on one hand -- and have several fingers left over. GW Pharmaceuticals (NASDAQ: GWPH) ranks as one of....
3 Growth Stocks With Virtual Monopolies
Monopolies can be bad. Having a single company control every aspect of an entire industry is likely to lead to higher consumer prices, slower innovation, and anticompetitive behavior.Lucky for us,....
3 Growth Stocks With Virtual Monopolies
Monopolies can be bad. Having a single company control every aspect of an entire industry is likely to lead to higher consumer prices, slower innovation, and anticompetitive behavior.Lucky for us,....
3 Growth Stocks With Virtual Monopolies
Monopolies can be bad. Having a single company control every aspect of an entire industry is likely to lead to higher consumer prices, slower innovation, and anticompetitive behavior.Lucky for us,....
Why Heron Therapeutics Stock Is Crashing Today
Heron Therapeutics (NASDAQ: HRTX), a commercial-stage biotech developing medicines to address unmet medical needs, saw its shares drop by as much as 11.8% today on over five times the average....